Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept
Tilman Speicher, Caroline Burgard, Florian Rosar, Moritz Bastian, Mark Bartholomä, Stephan Maus, Samer Ezziddin
Source record
Source: Crossref
Published: Apr 30, 2025
DOI: 10.1097/rlu.0000000000005938
Open original source ↗Source abstract
We present a 67-year-old man with inoperable metastatic G3 NET of the pancreas. The lesions were intensely positive in [ 68 Ga]Ga-DOTATOC PET/CT and only weakly positive in the supplementary [ 18 F]-FDG PET/CT. Peptide receptor radionuclide therapy (PRRT) with [ 177 Lu]Lu-DOTA-octreotate, after longstanding efficacy with repetitive retreatments over 7 years, eventually resulted only in disease stabilization without partial regression of lesions. After switching PRRT to the somatostatin receptor antagonist [ 177 Lu]Lu-DOTA-LM3, a marked therapy response was observed, in remarkable contrast to the stable disease effect of 177 Lu-octreotate seen right before. This interesting image illustrates the superior therapeutic efficacy of somatostatin antagonist PRRT over agonist-based PRRT.
Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.